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Summary
Branded in 2005, “neglected tropical diseases” have gained
traction in terms of advocacy, interest for research, en-
hanced funding and political will for their control and even-
tual elimination. Starting with an initial set of 13 neglected
tropical diseases – seven helminth, three bacterial and three
protozoal infections – the list considerably expanded to
more than 40 diseases that now also includes viral, fungal
and ectoparasitic infections. In this review, we provide a
comprehensive overview of the neglected tropical diseases,
their causative agents and the current geographical distri-
bution, including their importance for the general practi-
tioners seeing returning travellers and migrants in Switzer-
land. We characterise the most important of the neglected
tropical diseases in terms of at-risk population, estimated
number of infections, annual mortality rates and global bur-
den, including current knowledge gaps. With an emphasis
on neglected tropical diseases due to helminths, protozoa
and ectoparasites, we review common diagnostic methods
and current recommendations for treatment at the popula-
tion level and the individual patient, thereby juxtaposing
the situation in highly endemic countries on one side, with
Switzerland on the other. We highlight the clinical present-
ation and management of the neglected tropical diseases in
general and then elaborate on two examples, strongyloidi-
asis and leptospirosis. Our review provides a global per-
spective of neglected tropical diseases and we hope that it
will prove useful for the general practitioner and clinician
in Switzerland and elsewhere to enhance their suspicion in-
dex, differential diagnosis, clinical management and treat-
ment, including referral to specialised clinics and laborat-
ories when need be.
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Introduction
Diseases such as malaria, tuberculosis and HIV/AIDS are
well known causes of major global mortality, morbidity
and burden. Their negative impact on the social and eco-
nomic development of the most severely affected countries
has been emphasised [1–4]. Indeed, these “big three” are
responsible for several million deaths every year and tens
of millions of disability-adjusted life years (DALYs),
which, in turn, exacerbates poverty [5–8]. Interestingly
though, in two short assays pertaining to science, medicine
and society, along with a comprehensive 25-year review
of drug development efforts, published in leading journals
a decade ago [9–11], malaria, tuberculosis and HIV/AIDS
were still considered neglected diseases. In the meantime,
funding for research and development of new tools has
come to scale, and public-private partnerships and numer-
ous initiatives have been put into place for the prevention,
control and eventual elimination of the “big three”. Clearly,
the creation of the Global Fund to Fight AIDS, Tubercu-
losis and Malaria, in 2002, considerably altered the funding
landscape, and large-scale implementation of control inter-
ventions has saved millions of lives [7, 12–14].
However, a host of viral, bacterial, ectoparasitic, fungal,
helminth and protozoal diseases that occur mainly in the
tropics and subtropics remain truly neglected, and hence
the phrase “neglected tropical diseases” [15–18] is applied
to characterise these diseases. Reasons for this neglect are
many-fold. Among others, important issues are the intimate
connection of these diseases with poverty, geographical
isolation, stigmatisation, paucity of data regarding local
and global burden estimates, insufficient political and fin-
ancial resources for their control, lack of lobbies for the
most vulnerable population groups who are most severely
affected by these diseases, and fragmented funding mech-
anisms [16, 19–22].
In the present review, we provide an overview of the neg-
lected tropical diseases from a global perspective. We first
address the question why and when this “brand-name” was
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coined, including implications for advocacy, policy, public
health and research. Second, we put forth a comprehensive
list of neglected tropical diseases, their causative agents
and geographical distribution and highlight their import-
ance for tourists, returning travellers, long-term expatriates
and migrants in Switzerland. Given the large and growing
size of the list, we then focus on the most important neg-
lected tropical diseases, and characterise them in terms of
the at-risk population, number of infections, mortality rates
and global burden estimates. Knowledge gaps are identi-
fied and briefly discussed. The centre-piece of our review
pertains to the diagnosis, clinical management and treat-
ment of neglected tropical diseases. Emphasis is placed on
helminth and protozoal infections and we focus on the situ-
ation in Switzerland within the global perspective. Hence,
throughout our review, we highlight issues that are of par-
ticular relevance for the general practitioners, clinicians
and reference laboratory personnel in Switzerland. We be-
lieve that issues discussed are central also for other coun-
tries in Europe, North America and elsewhere.
Neglected tropical diseases
Origin of a ‘brand-name’
A search on PubMed, performed on 19 September 2012,
using the term “neglected tropical diseases”, revealed 730
hits. This search brought to bear that the first articles, ed-
itorials and personal viewpoints using the term “neglected
diseases” in the title appeared in 2001/2002. For example,
an interesting case study from India discussed the need
for establishing local research and development capacity
for neglected infectious and tropical diseases, emphasising
medicines [23]. The lack of funds for research and devel-
opment and the obviously limited interest of the industry to
invest in diseases of poverty made this term necessary for
researchers as well as public and private investors. In the
same vein, a systematic review covering a 25-year period
(1975–2000) revealed that virtually no new chemical entit-
ies were specifically developed for neglected diseases [10].
Hence, the need for efficacious, safe, easy-to-use and af-
fordable drugs was discussed at a conference organised by
Médecins Sans Frontières in early 2002 [9]. The pivotal
role of public-private partnerships to stimulate discovery,
development and deployment of new drugs for neglected
diseases was stressed. This resulted, in 2003, in the creation
of the Geneva-based Drugs for Neglected Diseases initi-
ative (DNDi; http://www.dndi.org) [10, 11, 24]. Of note,
the paucity of accurate, robust and rapid diagnostics for
one of the “big three” motivated the Bill & Melinda Gates
Foundation (BMGF) to put forward a 5-year start-up grant,
which helped to set up, also in 2003 and again based in
Geneva, the Foundation for Innovative New Diagnostics
(FIND; http://www.finddiagnostics.org/). FIND has gradu-
ally expanded its portfolio of activities with a growing em-
phasis on developing and validating novel diagnostics not
only for tuberculosis, but also the other two of the “big
three”, as well as truly neglected diseases, such as human
African trypanosomiasis, leishmaniasis and Chagas disease
[25, 26].
The first published paper with the full term “neglected
tropical diseases” in the title was a piece put forward by
Molyneux, Hotez & Fenwick, in November 2005 in PLoS
Medicine [15], closely followed by another landmark paper
in the same journal written by Hotez and colleagues [16].
The authors discussed a strategy of regular, large-scale ad-
ministration of drugs for morbidity control due to neglec-
ted tropical diseases, and outlined how this drug-based in-
tervention could be integrated within the control of the
“big three”. An accompanying expert commentary critic-
ally examined the strengths and limitations of the pro-
posed strategy [27]. A subsequent review by Hotez and col-
leagues entitled “Neglected tropical diseases”, published
in the New England Journal of Medicine clearly demon-
strated that the term “neglected tropical diseases” had be-
come mainstream [28].
Of note, in October 2007, the Public Library of Sciences
published the inaugural issue of a new open-access journal,
PLoS Neglected Tropical Diseases [29]. As of late Septem-
ber 2012, more than 1,600 original research papers, editor-
ials, expert opinions, viewpoints and other magazine-type
articles have been published. In Swiss Medical Weekly, thus
far, only a single article has been published when entering
the search term “neglected tropical diseases” [30].
What is meant by neglected tropical diseases?
Neglected tropical diseases refer to a group of mainly
chronic, debilitating and often stigmatising diseases that
primarily affect the poorest of the poor living in remote
rural and deprived urban settings of tropical and subtrop-
ical countries [16, 18, 21, 31–33]. Typical features of the
neglected tropical diseases are their intricate interrelation-
ships with poverty and social-ecological systems [21, 34,
35]. These diseases are associated with negative effects
on the course and outcome of pregnancy, delayed physical
and intellectual development during childhood and reduced
working productivity in older age [28, 36].
Evolving scope of the neglected tropical diseases
The two seminal papers published in 2005 and 2006
provided a list of 15 neglected tropical diseases, 13 of
which were deemed of particular importance in terms of
annual mortality rates and global burden [15, 16]. This list
of 15 diseases formed the initial scope of PLoS Neglected
Tropical Diseases. Included were nine helminth infections
(cysticercosis/taeniasis, drancunculiasis [guinea worm],
food-borne trematodiasis, lymphatic filariasis, onchocer-
ciasis, schistosomiasis and the three main soil-transmitted
helminthiases [ascariasis, hookworm infection and trichuri-
asis]), three protozoal infections (Chagas disease, human
African trypanosomiasis and leishmaniasis) and three bac-
terial infections (Buruli ulcer, leprosy and trachoma).
Interestingly, at the time, the World Health Organization
(WHO) featured some additional diseases on their list of
neglected tropical diseases, namely cholera/epidemic
diarrhoeal disease, dengue/dengue haemorrhagic fever and
endemic treponematoses (e.g., yaws, pinta and syphilis)
[18, 37]. Meanwhile, the list of neglected tropical diseases
has been further expanded and currently comprises over 40
diseases, which is reflected in the escalating scope of PLoS
Neglected Tropical Diseases [38]. Table 1 provides a com-
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prehensive overview of these 40+ neglected tropical dis-
eases, stratified into helminth, protozoal, bacterial, fungal,
viral and ectoparasitic infections. For each disease, the
causative agent(s) and the current endemic areas are sum-
marised. Moreover, the presence, management and relative
importance of these diseases for tourists, long-term travel-
lers and migrants in Switzerland is given, based on a com-
bination of national statistics, case reports, the authors’ col-
lective expertise and experience and useful input from two
anonymous referees.
Global burden of neglected tropical diseases
Table 2 summarises the main parasitic neglected tropical
diseases (helminth and protozoal infections) in terms of the
at-risk population, number of infections, annual mortality
rates and global burden of disease estimates. For compar-
ison, the “big three” are also listed in table 2. Some au-
thors have argued that the collective global burden due to
the 13 most important neglected tropical diseases exceeds
that of malaria and tuberculosis and is close to that of HIV/
AIDS [16], which spurred advocacy for the integrated con-
trol of neglected tropical diseases [17, 39, 40]. Indeed, ac-
cording to data presented by Hotez and colleagues, which
is largely derived from technical reports of WHO and the
annex table 3 of the world health report 2004, the collective
global burden of the initial set of 13 neglected tropical dis-
eases amounts to 56.6 million DALYs, which is higher than
that due to malaria (46.5 million DALYs) and tuberculosis
(34.7 million DALYs). However, it must be noted that there
are considerable uncertainties regarding global burden es-
timates, and the neglected tropical diseases proved partic-
ularly challenging for estimating global burden estimates
[18, 41–43]. For example, two different WHO sources re-
veal a more than 300-fold difference regarding the estim-
ated global burden due to hookworm infection. While the
lower estimate is as little as 59,000 DALYs [44], the up-
per estimate is 22.1 million DALYs [45] with the differen-
ce mainly explained by whether or not anaemia is partially
accounted for by hookworm infections. It is hoped that cur-
rent efforts to re-estimate the global burden of more than
175 diseases, injuries and risk factors will fill current gaps
and resolve discrepancies [46].
Diagnosis
While the primary indices of an infection are mostly the
presentation of clinical signs and symptoms, outcomes due
to an infection with neglected tropical diseases are often
unspecific, if signs and symptoms are present at all. Yet, an
accurate and early diagnosis is important for adequate pa-
tient management and treatment [47–49]. The lack of rapid,
accurate, simple-to-use, point-of-care tests for many of the
neglected tropical diseases is an important feature for their
general neglect and the under-appreciation of their disease
burden [50, 51].
The diagnosis of neglected tropical diseases, and partic-
ularly the detection of the endoparasitic infections em-
phasised here, is primarily based on well established and
widely used laboratory techniques, such as the examination
of blood, stool and urine samples under a microscope. As
shown in table 3, the mainstay to detect intestinal hel-
minths and protozoan infections is the visualisation of hel-
minth eggs or larvae and protozoan cysts or trophozoites,
respectively, in stool smears [50, 52–54]. Lymphatic filari-
asis, acute or congenital Chagas disease and human Afric-
an trypanosomiasis are diagnosed through the microscopic
identification of microfilariae or trypomastigotes in blood
and other body fluids [55–60]. Leishmaniasis is confirmed
by the isolation and visualisation of the amastigote parasite
stage from tissue [61–63]. Noteworthy, the reliable iden-
tification of parasitic infections requires in-depth training
for specimen preparation, and expertise and experience for
subsequent microscopic examination. While microscopy of
parasites is considered as highly specific, its sensitivity de-
pends on the intensity of infection, which is a function of
the number of parasitic elements in a sample [49, 64, 65].
For the diagnosis of chronic Chagas disease, echinococcos-
is, toxocariasis and trichinellosis, the direct documentation
of the infecting parasite is difficult and immuno-assays as
well as physical imaging techniques or trichinelloscopy, re-
spectively, are applied [54, 60, 66–68].
Immunodiagnosis is applicable for most of the neglected
tropical diseases, but may lack sensitivity and/or speci-
ficity. While some serological tests show excellent per-
formance (i.e., for the diagnosis of Chagas disease and vis-
ceral leishmaniasis), or are particularly useful when para-
site loads are low or for patients from non-endemic coun-
tries (i.e., for the diagnosis of schistosomiasis and
strongyloidiasis), others are highly error-prone. For ex-
ample, antibodies produced against one helminth species
are known to cross-react with antigens from other hel-
minths [66, 69]. Moreover, antibodies produced against in-
fectious agents do not give any indication of the severity of
infection [70], and are often detectable for several months
or years after an infection has cleared, and hence do not
allow to distinguish between current and past infections
[71–74]. In European clinics specialised for returning trav-
ellers and migrants, immunodiagnosis applied in combina-
tion with physical imaging or microscopy, and particularly
in consideration of disease history and clinical outcome, is
a valuable tool for the assessment of neglected tropical dis-
eases. The commercial availability of standardised test kits
is still the exception rather than the norm. Indeed, often
high-valuable in-house antigen preparations and tests are
in use, but efforts are underway to develop rapid diagnost-
ic tests that can be used at the point-of-care in developing
countries [51].
The development and use of molecular tools such as poly-
merase chain reaction (PCR) tests for the diagnosis of neg-
lected tropical diseases is the focus of multiple research
groups, but the commercial availability of DNA amplific-
ation kits is rare. Moreover, the isolation of parasite DNA
from stool or tissue is challenging, cumbersome and quite
often not fruitful at all [72]. Nevertheless, progress has
been made with molecular high-throughput multiplexing.
For example, multiplex real-time PCR assays have been
developed and are increasingly being utilised in a special-
ised laboratory in Leiden, the Netherlands for differential
diagnosis of helminths and intestinal protozoan infections
[75–77]. Hence, according to some authors, multi-parasit-
ic screenings based on molecular assays might one day re-
place microscopy and immunodiagnosis, at least in spe-
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Table 1: Neglected tropical diseases, stratified by helminthic, protozoal, bacterial, fungal, viral and ectoparasitic infections, including causative agents, current endemic
areas and their relative importance for tourists, long-term travellers and migrants in Switzerland.
Neglected tropical
disease
Causative agent(s) Endemic areas Trans-
mission in
Switzer-
landa
Manage-
mentb
Tou-
ristsc
Long-
term
travel-
lersc
Mi-
grantsc
Refe-
rence(s)
Helminth infections
Taenia solium Worldwide (pig breeding), mostly South
and Central America, sub-Saharan
Africa, Asia
° ((+)) (+) + [115, 116]
Taenia saginata Worldwide (cattle breeding), mostly sub-
Saharan Africa, Middle East, South and
Central America
((+)) (+) + [117]
Cysticercosis/
taeniasis
Diphyllobothrium latum Worldwide, mostly Northern Hemisphere
(America, Asia, Europe)
((+)) (+) + [118]
Dracunculiasis Dracunculus medinensis Ethiopia, Mali, South Sudan (Chad) (+) (+) ((+)) [119, 120]
Echinococcus granulosus Global distribution (pastoral
communities), particularly South
America, Mediterranean, Eastern
Europe, Near and Middle East, East
Africa, Central Asia, China, Russia
° (+) (+) + [116, 121,
122]
Echinococcosis
Echinococcus
multilocularis
Central and Eastern Europe, Near East,
Russia, China, Northern Japan
°° ((+)) ((+)) ((+)) [116, 121,
122]
Enterobiasis Enterobius vermicularis Global distribution (highest rates in
developing countries)
+ + + [123]
Food-borne trematodiasis
- Clonorchiasis Clonorchis sinensis China, Republic of Korea, Taiwan ° ((+)) (+) + [124, 125]
- Fascioliasis Fasciola gigantica, F. hepatica Bolivia, Chile, Cuba, Ecuador, Egypt,
France, Islamic Republic of Iran, Peru,
Portugal, Spain
(F. hepatica)
°° ((+)) (+) + [124, 125]
- Intestinal fluke
infections
Echinostoma spp., Fasciolopsis buski,
Metagonimus spp., Heterophyidae
Bangladesh, Cambodia, China, India,
Indonesia, Lao PDR, Malaysia,
Philippines, Taiwan, Thailand, Vietnam
°° ((+)) (+) + [124]
Opisthorchis felineus Kazakhstan, Russian Federation,
Siberia, Ukraine
°° ((+)) (+) + [124, 125]- Opisthorchiasis
Opisthorchis viverrini Lao PDR, Thailand, Vietnam,
(Cambodia)
°° ((+)) (+) + [124, 125]
- Paragonimiasis Paragonimus spp. Cameroon, China, Costa Rica, Ecuador,
Equatorial Guinea, Gabon, Guatemala,
India, Japan, Lao PDR, Liberia,
Malaysia, Mexico, Nepal, Nigeria,
Pakistan, Panama, Peru, Philippines,
Republic of Korea, Siberia, Sri Lanka,
Taiwan, Thailand, Vietnam
°° ((+)) (+) + [124, 125]
Loiasis Loa loa Central and West Africa (rainforest and
some savannah areas)
°°° ((+)) (+) + [126]
Lymphatic filariasis Wuchereria bancrofti, Brugia malayi,
B. timori
Africa, Asia, Central and Southern
America
°° ((+)) (+) + [127]
Mansonellosis Mansonella perstans, M. streptocerca,
M. ozzardi
Central and South America, Caribbean,
sub-Saharan Africa
°° ((+)) (+) (+) [59]
Onchocerciasis Onchocerca volvulus Africa, small foci in Southern and Central
America
°° ((+)) (+) + [127]
Schistosoma haematobium Sub-Saharan Africa, Middle East, some
islands in the Indian Ocean
° (+) + ++ [128, 129]
S. guineensis, S. intercalatum Parts of Central and West Africa ° (+) ((+)) (+) [128, 129]
S. japonicum China, Indonesia, Philippines ° ((+)) (+) + [128, 129]
S. mansoni Sub-Saharan Africa, parts of South
America (e.g., Brazil), some Caribbean
islands
° (+) + ++ [128, 129]
Schistosomiasis
S. mekongi Cambodia, Lao PDR ° ((+)) (+) + [128, 129]
Soil-transmitted helminthiasis
- Ascariasis Ascaris lumbricoides Global distribution (+) + ++ [83, 130]
- Hookworm
infection
Ancylostoma duodenale, Necator
americanus
Global distribution (+) + ++ [83, 130]
- Strongyloidiasis Strongyloides stercoralis Global distribution °° (+) + ++ [54, 83]
- Trichuriasis Trichuris trichiura Global distribution (+) + ++ [83, 130]
Toxocariasis Toxocara canis, T. cati Global distribution ° ((+)) (+) + [54, 131]
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Trichinellosis Trichinella spiralis and other Trichinella
spp.
Global distribution ° ((+)) (+) (+) [54, 67]
Protozoal infections
Chagas disease Trypanosoma cruzi Latin America °° ((+)) (+) +-++ [56, 60]
Human African
trypanosomiasis
Trypanosoma brucei gambiense,
T. brucei rhodesiense
Africa °°° ((+)) ((+)) ((+)) [58, 109,
133]
Intestinal protozoan infections
- Amoebiasis Entamoeba histolytica Global distribution (highest rates in
developing countries)
° (+) + ++ [134]
- Balantidiasis Balantidium coli South America, Middle East, Philippines,
Papua New Guinea
° ((+)) (+) + [132]
- Giardiasis Giardia intestinalis (syn.: G. duodenalis,
G. lamblia)
Global distribution (highest rates in
developing countries)
°, in case
of
treatment
failure
+ ++ ++ [135]
Leishmaniasis Visceral leishmaniasis: Leishmania
donovani, L. chagasi, L. infantum
(Muco-)cutaneous leishmaniasis:
L. major, L. tropica, L. braziliensis,
L. mexicana and other Leishmania spp.
Indian subcontinent, Asia, Africa,
Mediterranean basin, South America
(Ticino) °°° (+) + + [61-63]
Bacterial infections
Bartonellosis Bartonella henselae and other Bartonella
spp.
Global distribution ° ((+)) (+) (+) [136]
Bovine tuberculosis
in humans
Mycobacterium bovis Global distribution (highest rates in
developing countries)
°° ((+)) ((+)) (+) [137]
Buruli ulcer Mycobacterium ulcerans Australia, Guyana, Malaysia, Mexico,
Papua New Guinea, Peru, Sri Lanka,
West and Central Africa
°° ((+)) ((+)) (+) [138, 139]
Enteric bacterial infections
- Cholera Vibrio cholerae Recent outbreaks in Southern and
Central Africa (Angola, Democratic
Republic of the Congo, Guinea-Bissau,
Republic of the Congo, Tanzania,
Zimbabwe), Central America (Dominican
Republic, Haiti), Asia (Cambodia, Indian
subcontinent, Malaysia, Papua New
Guinea, Thailand)
° (+) (+) (+)-+ [140]
- ETEC infection Enterotoxigenic Escherichia coli (ETEC) Global distribution (highest rates in
developing countries)
++ ++ ++ [141]
- Salmonellosis Non-typhoidal salmonellosis: Salmonella
enterica serovars S. Enteridis,
S.Typhimurium and other serovars
Enteric fever: S.enterica serovars
S. Typhi, S. Paratyphi
Global distribution (highest rates in
developing countries)
+ + ++ [142]
- Shigellosis Shigella dysenteriae, S. boydii,
S. flexneri, S. sonnei
Global distribution (highest rates in
developing countries)
+ + + [143]
Leprosy Mycobacterium leprae Brazil, China, Guinea, India, Indonesia,
Madagascar, Mozambique, Myanmar,
Nepal, Philippines, Sudan, Vietnam,
other tropical and sub-tropical regions
°°° ((+)) (+) (+) [144]
Leptospirosis Leptospira interrogans group Global distribution (highest rates in
developing countries)
(+) (+) (+) [98]
Relapsing fever Borrelia recurrentis, B. duttoni and other
Borrelia spp.
Africa (highest rates), parts of the
Americas, Asia, Europe
(+) (+) (+) [145]
Trachoma Chlamydia trachomatis Africa, Middle East, Mexico, large parts
of Asia and South America, Australia
((+)) ((+)) ((+)) [146]
Treponematoses
(bejel, pinta, syphilis,
yaws)
Treponema pallidum Global distribution (highest rates in
tropical regions)
(syphilis) ° (+) (+) + [147]
Fungal infections
Mycetoma (“Madura
foot”)
Various fungi (eumycetoma) and bacteria
(actinomycetoma, pseudomycetoma)
“Mycetoma belt” between latitudes of 15°
South and 30° North (Africa, India,
Yemen, Central and South America)
° ((+)) ((+)) (+) [148, 149]
Paracoccidiomycosis Paracoccidioides brasiliensis Brazil (80%), Venezuela, Colombia,
Ecuador, Argentina, Mexico, parts of
Central America
°° ((+)) ((+)) ((+)) [150]
Viral infections
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Dengue Dengue fever virus (genus: Flavivirus) South-East Asia, Central and South
America, Pacific Islands, Indian
subcontinent, occasionally in parts of
Africa and Northern Australia
++ ++ ++ [151]
Japanese
encephalitis
Japanese encephalitis virus (genus:
Flavivirus)
South-East Asia (rice agriculture, pig
farming), Indian subcontinent,
sporadically in Northern Australia and the
Western Pacific
°° ((+)) ((+)) (+) [152, 153]
Yellow fever Yellow fever virus (genus: Flavivirus) West and Central Africa, South America,
occasionally in East Africa and Central
America
°° ((+)) ((+)) (+) [151, 154]
Rabiesd Rabies virus (genus: Lyssavirus) Global distribution (highest incidence in
Africa, Asia, South and Central America,
Eastern Europe)
(European
bat-rabies)
°° (+) ++ ++ [155]
Rift Valley fever Rift Valley fever virus (genus:
Phlebovirus)
Arabian Peninsula and whole Africa
(especially North-East, West and South-
Central Africa, including Madagascar)
°° ((+)) ((+)) ((+)) [156]
Viral haemorrhagic
fevers
Important Arenaviridae: Lassa virus,
Chapare virus, Guanarito virus, Junín
virus, Machupo virus, Sabiá virus
Bunyaviridae: Crimean-Congo
haemorrhagic fever virus (HFV), Hanta
viruses including Puumala virus
Filoviridae: Ebola virus, Marburg virus
Flaviviridae: Omsk HFV, Kyasanur forest
disease virus
South America (Argentina, Bolivia, Brazil,
Venezuela)
Lassa virus: West Africa (Guinea, Liberia,
Nigeria, Sierra Leone)
Crimean-Congo HFV: South-Eastern
Europe (especially Bulgaria), Turkey,
South-West Russia, Arabian Peninsula,
Central Asia, Africa
Hanta virus: Global distribution
Filoviridae: Angola, Democratic Republic
of the Congo, Gabon, Kenya, Republic of
the Congo, Sudan, Uganda
Omsk HFV: West Siberia
Kyasanur forest disease: India
(Hantavirus:
Nephropathia
epidemica)
°°° ((+)) ((+)) ((+)) [157]
[158]
[159]
[160]
[161]
[162]
[162]
Ectoparasitic infections
Myiasis Parasitic fly larvae (Calliphoridae,
Oestridae, Sarcophagidae and others)
Global distribution (highest incidence in
tropical and subtropical countries)
(+) + + [163]
Scabies Sarcoptes scabiei Global distribution (highest incidence in
tropical and subtropical countries)
+ + + [164]
a Consultation with specialist in tropical medicine: ° = helpful; °° = important; °°° = necessary.
b (CH): can be transmitted autochthonously in Switzerland and/or neighbouring European countries.
c +-+++ = existing to heavy risk; (+) = low risk; ((+)) = very low risk; – = no risk.
d Grading refers to dog or other animal bites.
cialised laboratories in the industrialised world [78]. An
advantage of microscopy though, is that it is an untargeted
approach, and hence well trained laboratory technicians
might detect an infection that would have been missed by a
more targeted molecular approach [50].
As discussed in the next section under the example of clin-
ical management of strongyloidiasis, to avoid false neg-
ative results due to the lack of sensitivity of any single
diagnostic technique, examination of multiple specimens
obtained over consecutive days and the combination of dif-
ferent methods is recommended [74, 79, 80]. The devel-
opment of advanced and standardised sensitive diagnostic
approaches that are practicable and affordable not only in
well equipped laboratories of the North, but also in devel-
oping country settings is of prime importance to identify
and tackle neglected tropical diseases [81].
Clinical management
General considerations
The signs and symptoms of the various neglected tropical
diseases are perhaps as diverse as the different infectious
agents involved in their pathogenesis. The spectrum of pos-
sible clinical presentations ranges from asymptomatic in-
fection to fulminant life-threatening or to chronic debilit-
ating conditions. As virtually all organs can be affected,
a high suspicion index and knowledge about the different
groups of tropical pathogens can assist clinicians for an
early recognition and timely diagnosis of these infections
in returning travellers, long-term expatriates, migrants and
patients from endemic areas, based on knowledge of the
respective geographical epidemiology. Clinical signs and
patient complaints are often indistinctive, thus seldom al-
lowing a specific diagnosis based on history and clinical
examination alone without knowledge of epidemiology and
further diagnostic work-up.
Table 4 comprises common clinical presentations of selec-
ted parasitic neglected tropical diseases. Despite many sim-
ilarities, some infections exhibit unique features clinicians
should know about, as they may be encountered in the trop-
ics as well as in temperate regions (e.g., in Switzerland and
elsewhere in Europe). Due to space restrictions in this re-
view, only two neglected tropical diseases are presented
in greater detail: (i) strongyloidiasis (a helminth infection
that might be fatal in immunocompromised patients) and
(ii) leptospirosis (a bacterial infection that might cause out-
breaks and is emerging in Europe). For a third example
– Chagas disease (caused by a protozoon infection that is
emerging in Switzerland due to the growing number of Lat-
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in American migrants) – the reader is referred to a recent
excellent review by Jackson and Chappuis [82].
Strongyloidiasis
While the three main soil-transmitted helminth species
(i.e., Ascaris lumbricoides, Trichuris trichiura and hook-
worm) are easily diagnosed and cause mainly chronic, of-
ten asymptomatic infections that usually respond well to
empiric treatment with albendazole or mebendazole, par-
ticular attention has to be paid to the diagnosis and clinical
management of Strongyloides stercoralis (threadworm).
Figure 1 shows the life cycle of S. stercoralis. In contrast to
the common soil-transmitted helminths [54, 83], S. stercor-
alis is able to replicate within the intestines of infected indi-
viduals for long time periods (autoinfection) [54, 84]. The
larvae hatch in the gut and are able to penetrate the intestin-
al mucosa, from where they may spread to all organs [85].
As these tissue-invasive larvae carry bacteria on the sur-
face, their migration can lead to systemic infections with
septicaemia, leading to a high fatality rate (hyperinfection
syndrome). Such dissemination may occur even decades
after the first contact, so that the absence of recent travel to
endemic areas is never sufficient to exclude strongyloidias-
is as a potential differential diagnosis in symptomatic pa-
tients. Asymptomatic strongyloidiasis must be ruled out in
patients requiring immunosuppressive treatment who may
have experienced exposure, as this parasite may flare up
as a life-threatening infection. Symptoms may be absent or
unspecific in healthy individuals, but can rapidly evolve in
immunosuppressed hosts [86].
The diagnosis of S. stercoralis is challenging, as micro-
scopy of stool samples usually fails to detect the larvae
(table 3). Hence, more laborious techniques have to be em-
ployed (e.g., agar plate culture and Baermann funnel tech-
nique), but the sensitivity of these methods is usually lim-
ited [80]. Multiple examinations and the combination of
techniques enhance the diagnostic sensitivity [79, 80, 87,
88]. The direct demonstration of larvae in bronchoalveol-
ar lavages, bronchial or duodenal aspirates or faecal speci-
mens proves S. stercoralis infection, but lacks sensitivity in
Table 2: Current estimates for the global burden due to the most important neglected tropical diseases caused by helminthic and protozoal infections. For comparison, the
“big three” are also shown.
Disease At-risk
population
(millions)
No. of people
infected (millions)
No. of people with
morbidity (millions)
Death
(thousands)
Global burden
(thousand DALYs)
Refe-
rence(s)
Neglected tropical disease
Helminth infections
- Soil-transmitted helminthiasis
Ascariasis 5,416 807–1,221 350 3–60 1,817–10,500 [17, 83, 130]
Hookworm infection 5,346 576–740 150 3–65 59–22,100 [17, 83, 130]
Trichuriasis 5,307 604–795 220 3–10 1,006–6,400 [17, 83, 130]
Strongyloidiasis n.d. 30–100 n.d. n.d. n.d. [83]
- Lymphatic filariasis >1,000 120 43 0 5,777 [17, 127]
- Schistosomiasis 779 207 120 15-280 1,702–4,500 [17, 165]
- Food-borne trematodiasis
Clonorchiasis 601 15.3 1.1 5.6 275 [43, 124]
Paragonimiasis 292 23.2 5.3 0.2 197 [43, 124]
Fascioliasis 91 2.6 0.3 0 35 [43, 124]
Opisthorchiasis 80 8.4 0.3 1.3 74 [43, 124]
Intestinal fluke infections n.d. 6.7 0.9 0 84 [43, 124]
- Onchocerciasis 120 37 n.d. 0.05a 484 [127, 166]
- Cysticercosis/taeniasis n.d. n.d. n.d. n.d. >2,000 [117]
- Echinococcosis n.d. n.d. n.d. n.d. >285 [122]
- Mansonellosis 581 (Africa) >114 (Africa) n.d. n.d. n.d. [59]
- Dracunculiasis n.d. 0.001 0.001 n.d. <100 [119]
- Enterobiasis n.d. n.d. n.d. n.d. n.d. [123]
- Loiasis >29.6 >9.2 n.d. 0 n.d. [167]
- Toxocariasis n.d. n.d. n.d. n.d. n.d. [131]
- Trichinellosis n.d. n.d. n.d. n.d. n.d. [67]
Protozoal infections
- Leishmaniasis 350 12 n.d. 70 2,090–2,400 [44, 61, 168]
- Chagas disease 120 8 n.d. 14 667 [56]
- Human African trypanosomiasis >60 >0.03 n.d. <10 n.d. [169]
- Intestinal protozoan infections
Amoebiasis n.d. n.d. n.d. 40–100 n.d. [53, 134]
Giardiasis n.d. n.d. 200 n.d. n.d. [135]
Balantidiasis n.d. n.d. n.d. n.d. n.d. [132]
The “big three”
Malaria 2,211 n.d. 515 889–1,272 34,000–46,490 [8, 44, 170, 171]
HIV/AIDS n.d. 33.3 n.d. 1,800–2,777 58,500–84,500 [44, 171, 172]
Tuberculosis n.d. n.d. >8.8 1,464–1,566 34,200–34,700 [44, 171, 173]
a In the ‘Onchocerciasis Control Programme’ (OCP) area [174]. n.d. = not determined.
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Table 3: Clinical hints and methods for the diagnosis of parasitic neglected tropical diseases (due to helminth, protozoal and ectoparasitic infections)a.
Neglected tropical disease Diagnosis in travel clinics Refe-
rence(s)
Helminth infections
Cysticercosis/taeniasis Suspicion upon neurological symptoms plus cystical central nervous system (CNS) lesions. Combination of questioning,
parasitological examination, immunodiagnosis, molecular methods or imaging.
• Stool microscopy
• Perianal egg detection (Graham’s test applying adhesive tape)
• Morphological examination of tapeworms from purges
• Coproantigen detection by enzyme-linked immunosorbent assay (ELISA)
• Serology: detection of species-specific circulating antibodies against T. solium
• Molecular methods/copro-DNA assays (i.e. polymerase chain reaction [PCR])
[74]
Dracunculiasis Visual detection of a blister and the emerging female worm [175]
Echinococcosis Suspected in patients with abdominal fullness and/or dyspnoea leading to detection of cystic lesions. Immunodiagnostic
methods (for primary serological screenings, to confirm clinical findings and for follow-up of patients after surgical or
pharmacological treatment) in combination with physical imaging techniques (for definitive diagnosis).
Detection of serum antibodies and parasite antigen with:
• Indirect haemagglutionation tests (IHAT)
• ELISA
• Immuno-blotting
Physical imaging methods:
• Radiology
• Ultrasonography
• Computed axial tomography (CT scanning)
• Nuclear magnetic resonance (NMR) imaging to detect cysts
PCR tests can help to identify Echinococcus-specific DNA in biological specimens resected or biopsied from patients.
[66]
Enterobiasis Perianal itching (irritability of small children), leading to detection of eggs and adult worms.
• Adhesive tape technique
[176, 177]
Food-borne trematodiasis Various abdominal symptoms leading to detection of eggs, adult worms, and parts of worms under a microscope,
immunological and molecular methods.
• Faecal examination to detect eggs (sedimentation, Kato-Katz, ether-concentration, McMaster, FLOTAC tech-
niques)
• Immunodiagnosis to detect worm-specific antibodies or antigens in serum or stool (counter-immunoelectrophores-
is, ELISA)
• Molecular methods to amplify DNA from eggs or other biological components or products of the worms (PCR)
Non-invasive imaging techniques to examine organ damage:
• Ultrasonography
• Magnetic resonance imaging
• Computerised tomography
• X-ray
[69, 74, 125]
- Clonorchiasis Detection of eggs in faeces or bile aspirates.
Imaging techniques to identify adult worms and lesions in the hepatic ducts.
[74]
- Fascioliasis Abdominal discomfort and fever.
• Detection of eggs in faeces or bile aspirates
• Imaging techniques to identify hepatic lesions and “tunnel-like” migration paths
[74]
- Intestinal fluke infections Faecal examination to detect parasite eggs (note that the parasite eggs of Fasciola, Fasciolopsis and Echinostoma and
of Opisthorchis, Clonorchis and Heterophyidae are difficult to differentiate):
• Stoll’s dilution
• Formalin-ether concentration
• Direct faecal smear
• Kato-Katz technique
Recovery of adult worms from purges after treatment.
[178]
[74]- Opisthorchiasis • Detection of eggs in faeces or bile aspirates
• Imaging techniques to identify adult worms and lesions in the hepatic ducts
• Detection of eggs in faeces or bile aspirates
• Imaging techniques to identify adult worms and lesions in the hepatic ducts
[74]
- Paragonimiasis • Detection of eggs in sputum
• Chest X-ray to identify nodules and opacities in the lung parenchyma or signs of pleuritis and pneumothorax
[74]
Review article: Current opinion Swiss Med Wkly. 2012;142:w13727
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 24
Filariasis The suspicion is based on cutaneous and lymphatic signs and symptoms, whereas the diagnosis of filariae relies on the
detection of microfilariae in blood or skin snip samples taken at a specific time at the day or night. New molecular
techniques (PCR) for the detection of filaria DNA are becoming more common but are not yet commercially available or
routinely applied.
[59]
- Loiasis Identification of clinical characteristics such as Calabar swelling or worm crossing the subconjunctival eye.
Detection and quantification of sheathed microfilariae in blood taken around noon.
• Thin and thick blood film stained with haematoxylin
• Concentration techniques, including sedimentation or filtration of blood may be required, if the microfilariaemia is
low
Ultrasonography to visualise the movements of living adult filarial worms.
Immunodiagnostic methods often lack sensitivity and they might cross-react with other filarial species.
PCR to amplify species-specific DNA is accurately detecting microfilariaemia and occult loiasis.
[179, 180]
- Lymphatic filariasis Microscopic examination of blood (taken at night) for sheathed microfilariae using low power:
• Counting chamber technique
• Thin and thick blood film stained with Giemsa
• Knott concentration technique
• Membrane (Nucleopore) filtration technique
Immunochromatographic tests (ICT) as card or ELISA are sensitive and specific for the detection of W. bancrofti
microfilariae carriers.
Molecular diagnostic techniques include PCR to detect filarial DNA in human blood samples (taken at night) and
molecular xenomonitoring (MX) to detect parasite DNA in pooled mosquitoes or human blood by PCR.
[181, 182]
- Onchocerciasis Diagnosis relies on the detection of unsheathed microfilariae under the skin:
• Detection of unsheathed microfilariae in skin snips under the microscope
• Diethylcarbamazine (DEC)-based patch test, which provokes an itchy papular rash when read 24-48 hours after
application
Newer techniques have been developed:
• Dipstick test to detect O. volvulus-specific antigen
• Three recombinant antigens cocktail
• PCR
[127, 183]
- Mansonellosis Microscopic examination of blood (taken anytime at day or night) for unsheathed microfilariae from M. perstans and M.
ozzardi.
• Counting chamber technique
• Thin and thick blood film stained with Giemsa or haematoxylin
• Knott concentration technique
• Membrane filtration
Microscopic identification of unsheathed microfilariae from M. streptocerca in skin snips stained with haematoxylin or
Giemsa.
[59]
Often asymptomatic, occasionally acute generalised disease with (Katayama) fever.
Microscopic detection of schistosome eggs in faeces or urine is the current mainstay of diagnosis in endemic settings.
The miracidium-hatching test can also be used to test infections.
Imaging techniques are used to identify schistosomiasis characteristic periportal and bladder fibrosis.
• Ultrasonography
• Computed tomography
• Magnetic resonance imaging
Most commercially available immunodiagnostic kits are not very sensitive or specific and cannot distinguish between
past and present infection.
A commercially available point-of-care cassette test to detect circulating cathodic antigen (POC-CCA) in urine is a
sensitive tool for S. mansoni diagnosis.
PCR-based assays that are specific and highly sensitive have been developed for the detection of schistosome DNA in
human excreta or sera and plasma, but need further validation and standardisation.
In patients with clinical signs but negative stool or urine examinations a biopsy of bladder or rectal mucosa must be used
for diagnosis.
[71, 184, 185]
For S. haematobium: filtration (Nucleopore) of 10 ml of urine or sedimentation (after centrifugation) of urine sample to
detect eggs under a microscope
[186]
Schistosomiasis
For S. mansoni, S. japonicum. S. mekongi, S. guineensis and S. intercalatum: detection of species specific eggs in stool
using
• Kato-Katz technique
• Formalin-ether concentration
• Sedimentation technique
• FLOTAC (first experiences for S. mansoni)
[187-189]
Soil-transmitted helminthiasis Often clinically asymptomatic.
Eggs or larvae of soil-transmitted species are routinely detected by microscopic examination of stool samples.
Immunological or molecular approaches are not widely applied due to cross-reactions and technical constraints to isolate
DNA from stool samples, respectively.
[49, 54]
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- Ascariasis Eggs can be detected by the application of the following methods:
• Kato-Katz technique
• Formalin-ether concentration
• Sedimentation technique
• McMaster technique
• FLOTAC
[65, 187, 188,
190, 191]
- Hookworm disease Signs and symptoms of anaemia.
Eggs can be detected by the application of the following methods:
• Kato-Katz technique
• Formalin-ether concentration
• Sedimentation technique
• McMaster technique
• FLOTAC
[65, 187, 188,
190, 191]
- Strongyloidiasis Gastrointestinal, cutaneous and respiratory signs and symptoms.
Larvae can be detected by the application of the following methods:
• Baermann method
• Koga agar plate method
Serology is considered a valuable tool for screening and evaluation of therapies in non-endemic target groups:
• ELISA
• IFAT
• Western blot
[85, 192, 193]
- Trichuriasis Eggs can be detected by the application of the following methods:
• Kato-Katz technique
• Formalin-ether concentration
• Sedimentation technique
• McMaster technique
• FLOTAC
[65, 187, 188,
190, 191]
Toxocariasis Cutaneous, respiratory or CNS (eye) symptoms.
Since the human is not the definitive host, no worm eggs can be identified in stool samples. The diagnosis relies on
immunodiagnosis, imaging techniques and biopsies of tissues and organs:
• Immunoassay (EIA) using standardised T. canis excretory-secretory (TES) antigens from infective-stage larvae to
diagnose visceral and ocular larva migrans
• Western blot to confirm positive results
• High resolution ultrasonography to reveal hypoechoic areas in the liver
[68, 194, 195]
Trichinellosis Muscle pain and fever. Besides the interpretation of the clinical picture, diagnosis relies on the detection of non-specific
parameters (eosinophilia, elevated level of muscle enzymes).
Immunodiagnostic methods and trichinelloscopy of a small muscle tissue sample:
• ELISA
• Western blot
• Counterimmunoelectrophoresis
• Latex agglutination
[67, 196, 197]
Protozoal infections
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Chagas disease Gastrointestinal and cardiac signs and symptoms.
Trypanosomes can be detected in the peripheral blood during the acute phase of infection by microscopy.
Trypomastigotes can be identified in:
• Thick blood films
• Buffy coat preparation (microhaematocrit technique)
• Serum precipitate (Strout’s technique)
• Centrifugation of blood after lysis of red cells with 0.87% ammonium chloride
To diagnose congenital infections, the following methods are applicable:
• Microhaematocrit
• PCR
Diagnosis in newborns relies on:
• Microscopic examination of cord blood or peripheral blood
• Test for anti-T. cruzi IgG antibodies
In the chronic phase of infection, the following techniques may be applied:
• Xenodiagnosis
• Blood culture
• ELISA
• Indirect immunofluorescencent antibody test (IFAT)
• Indirect haemagglutination
[56, 198]
Human African trypanosomiasis Cutaneous chancre and fever.
Diagnosis relies on visualisation of parasites in blood, lymph or cerebrospinal fluid (CSF). Of note, it is not possible to
discriminate T. brucei gambiense and T. brucei rhodesiense by microscopy. Clinical signs and serological or molecular
methods can provide only indirect evidence of an infection and the presence of parasites must be confirmed before
administering toxic treatment:
• Examination of finger-prick blood
• Thick blood film
• Haematocrit centrifugation
• Quantitative buffy coat technique combines haematocrit centrifugation with fluorescent detection (acridine orange)
of trypanosomes
• Mini anion exchange centrifugation technique (mAECT) to separate trypanosomes from red cells before centrifu-
gation
• Card agglutination trypanosomiasis test (CATT) for T. brucei gambiense
• LATEX/T. brucei gambiense test
• Immunofluorescence
• ELISA
• IHAT
• PCR
[57, 109, 199]
Intestinal protozoan infections
- Amoebiasis History of diarrhoea, abdominal discomfort and fever.
Cysts can be detected by the application of the following methods:
• Fresh stool preparation
• Formalin-ether concentration
• Sedimentation technique
Serological and molecular methods
[50, 53, 72]
- Balantidiasis Large motile trophic ciliates can be detected in fresh diarrhoeic faeces and bronchoalveolar wash fluid. Cyst stages are
more commonly found in formed stool.
• Wet mount slide preparations
• Concentration techniques (sedimentation or flotation)
Trophozoites can also be obtained from biopsies of the margins of ulcers identified with proctosigmoidoscopy.
[50, 132]
- Giardiasis Foul-smelling diarrhoea, bloating. Irritability (children).
Cysts can be detected by the application of the following methods:
• Fresh stool preparation
• Formalin-ether concentration
• Sedimentation technique
Serological and molecular methods
[50, 52]
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Leishmaniasis The parasite species can be identified using culture and DNA identification.
Cutaneous leishmaniasis:
• Microscopy to identify amastigotes in biopsies, scrapings, or impression smears, staining with the panoptic May
Grünwald-Giemsa stain or mouse anti-Leishmania immune serum and peroxidase coniugate
• Growth of promastigotes in Novy-MacNeal-Nicolle culture
• Serology has a limited application in the diagnosis of current cutaneous leishmaniasis and is not routinely used in
clinical practice
• PCR to detect parasite DNA in infected skin lesions
Visceral leishmaniasis:
• Microscopy to identify amastigotes in aspirates from lymph nodes, bone marrow or spleen
• Culture from aspirates of spleen, bone marrow, lymph node, or liver
• ELISA, IFA, Western blot, direct agglutination test (DAT), immunochromatographic test (ICT)
• PCR to detect parasites in blood or organs
[61, 200-202]
Ectoparasitic infections
Myiasis Diagnosis of furuncular myiasis solely based on clinical grounds. Imaging techniques can support the identification of
maggots within furuncles:
• Dermoscopy
• Ultrasonography
• Colour Doppler sonography
[163]
Scabies Clinical diagnosis by detection of severely itching burrows, lesions, papules, vesicles and pustules at typical predictor
sites. Microscopic detection of the mite, ova, or faecal pellets is specific, but not very sensitive.
[203–205]
a It is important to note that any parasitological diagnosis should always consider the clinical history of the patient.
patients with low worm loads. Recent advantages in sero-
logy, the development of a faecal antigen-capture enzyme-
linked immunosorbent assay (ELISA) for S. stercoralis and
the ongoing validation of a PCR approach will help to fur-
ther improve the diagnosis of strongyloidiasis [84, 88, 89].
Frequently affected organs are the gastrointestinal tract, the
skin and the lungs, whereas the central nervous system
(e.g., meningitis) is rarely affected (table 4). Possible
symptoms and clinical observations are diarrhoea, abdom-
inal bloating and tenderness, a skin rash, pruritus ani,
wheezing on pulmonary auscultation and chronic cough.
A distinctive, fast-moving cutaneous itchy eruption called
“larva currens” is sometimes observed by the patient and
peripheral blood eosinophilia is suggestive of parasitic in-
fection, but not always present.
Disseminated infection should always be excluded in pa-
tients on immunosuppressive long-term treatment, espe-
cially organ transplant recipients (e.g., following renal
Figure 1
Life cycle of Strongyloides stercoralis. (Adapted from Olsen A, van
Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al.
Strongyloidiasis – the most neglected of the neglected tropical
diseases? Trans R Soc Trop Med Hyg. 2009;103:967–72 [85]. ©
Elsevier, 2009. Printed with permission).
transplantation), and in symptomatic individuals from en-
demic areas with a history of chronic alcohol abuse [90]
or HTLV-1 co-infection, which is common in Japan, Ja-
maica, South America, sub-Saharan Africa and parts of
Asia [91]. Corticosteroids appear to activate hormone re-
ceptors of S. stercoralis larvae and might mediate the de-
velopment of a hyperinfection syndrome [92]. Hence, pa-
tients from endemic areas should be screened for asympto-
matic strongyloidiasis before starting immunosuppressive
medication. Due to the broad range of possible clinical
presentations, the decision to treat a patient suspected of
carrying S. stercoralis remains challenging. An indication
for treatment is usually given if at least two of the follow-
ing observational criteria are met: (i) pulmonary, abdomin-
al and/or skin symptoms, (ii) elevated peripheral eosinophil
count and (iii) positive serology [93]. However, all pa-
tients with a positive S. stercoralis serology prior to organ
transplantation should be treated to avoid the development
of a life-threatening hyperinfection syndrome. Recommen-
ded treatment options include albendazole and ivermectin,
whereas the latter has become the drug of choice to treat
strongyloidiasis [36, 92].
Leptospirosis
Leptospirosis is probably the most common zoonosis af-
fecting humans worldwide, with the highest disease burden
encountered in tropical and subtropical countries [94, 95].
Figure 2 depicts its life cycle. In brief, bacteria of the genus
Leptospira are spirochetes, able to survive in the envir-
onment for long time periods of time, especially in warm
and humid areas [95]. Pathogenic Leptospira spp. infect
many different kinds of mammals (e.g., rodents, pigs and
dogs), which excrete the bacteria in their urine. Human in-
fection occurs either by direct contact with infected anim-
als or indirectly through contact with urine-contaminated
water or soil. As the spirochetes easily penetrate human
skin, farmers using traditional methods of irrigating their
fields are at an elevated risk of infection [96]. While recre-
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Table 4: Organ-specific clinical manifestations of selected neglected tropical diseases (helminth and protozoal infections).
Disease Affected organ system
Central nervous
system
Cardio-
vascular
Pneumo-
logical
Gastro-
intestinal
Hepato-
biliary
Genito-
urinary
Cutaneous
Soil-transmitted helminthiasis
Ascariasis – – Cough, chest pain,
wheezing
(Loeffler’s syndrome =
pulmonary migration
of maturating
parasite)
Abdominal pain; in
severe infection:
nutritional
deficiency,
mechanical bowel
obstruction (in
children)
Rare: obstruction of
the bile or
pancreatic duct due
to aberrant parasite
migration
– –
Hookworm
infection
– Light to moderate
iron-deficiency
anaemia; rare:
cardiac failure due
to severe anaemia
in heavy infection
Cough, chest pain,
wheezing fever
(Loeffler’s syndrome =
pulmonary migration
of maturating
parasite)
Abdominal pain,
indigestion, nausea,
vomiting, diarrhoea
constipation; in
severe cases
ascites due to
protein deficiency
– – (Cutaneous larva
migrans: animal
hookworms)
Strongyloidiasis – – Cough, chest pain,
wheezing (Loeffler’s
syndrome =
pulmonary migration
of maturating
parasite)
Diarrhoea, bloating,
tenderness, blood in
the stool
– – Skin rash, larva
currens
Trichuriasis – – – Abdominal pain,
bloody diarrhoea
(leading to
anaemia); in severe
infection: rectal
prolapse
– – –
Schistosomiasis
Intestinal
schistosomiasis
Rare: neuro-
schistosomiasis
due to aberrant
oviposition
Pulmonary
hypertension
Cough, chest pain,
wheezing, fever
(acute
schistosomiasis =
allergic reaction to
maturating parasite)
Chronic or
intermittent (bloody)
diarrhoea,
abdominal pain
Hepatic fibrosis,
leading to portal
hypertension,
hepato-
splenomegaly,
gastrointestinal
bleeding from
varices
– Initially: localised
skin rash
(penetration site of
parasite at infection)
Later: urticarial skin
rash (allergic
reaction to
maturating parasite)
Urinary
schistosomiasis
Rare: neuro-
schistosomiasis
due to aberrant
oviposition
– Cough, chest pain,
wheezing, fever
(acute
schistosomiasis =
allergic reaction to
maturating parasite)
– – (Hepatic fibrosis) Painless
haematuria,
suprapubic
discomfort,
burning
micturation,
hydronephrosis
risk for bladder
cancer in chronic
cases
Initially: localised
skin rash
(penetration site of
parasite at infection)
Later: urticarial skin
rash (allergic
reaction to
maturating parasite)
Filariasis
Dracunculiasis – – – – – – Skin lesions,
bacterial
superinfection
Lymphatic
filariasis
– – Cough, wheezing,
fever (tropical
pulmonary
eosinophilia (TPE))
– – Funiculitis,
epididymitis,
hydrocele
Lymphadenitis,
lymphadenopathy,
lymphangitis
Loiasis Encephalopathy
(treatment
induced)
– – – – – Angiooedema,
(“Calabar”
swellings), pruritus,
subconjunctival
migration of adult
parasite
Review article: Current opinion Swiss Med Wkly. 2012;142:w13727
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 13 of 24
Mansonellosis Visual impairment,
loiasis-like eye
lesions
– Serositis Abdominal pain Hepatomegaly – Pruritus, papular
eruptions, rash,
reduced skin
pigmentation,
angiooedema,
loiasis-like
subcutaneous
swellings (due to
migration of adult
worm)
Onchocerciasis Eye lesions
(keratitis,
chorioretinitis,
neuritis,
blindness);
encephalopathy
(treatment
induced)
– – – – – Nodules, pruritus,
rash, skin atrophy
Leishmaniasis
Cutaneous/
mucocutaneous
– – – – – – Skin (or mucosal)
lesions (ulcers)
Visceral (Kala
azar)
– – – Anorexia, weight
loss
Fever, hepato-
splenomegaly,
pancytopenia,
hepatitis
–
Human African
trypanosomiasis
Meningo-
encephalitis
Perimyocarditis – Diarrhoea Fever,
hepatomegaly,
jaundice
– Skin ulcer
(“chancre”), rash,
(“trypanid”),
lymphadenopathy
Chagas disease Meningo-
encephalitis,
space occupying
lesions
Dilated
cardiomyophathy,
conduction
abnormalities
– Megacolon,
megaoesophagus
(Achalasia),
resulting in weight
loss, malnutrition
– – Romaña sign
(periorbital swelling
at conjunctival
inoculation of the
parasite)
Food-borne trematodiasis
Paragonimiasis Eosinophilic
meningitis (ectopic
parasite migration)
– Chest pain, cough,
haemoptysis, pleural
effusion, infiltrations,
pneumothorax
– Hepatomegaly – Urticaria, aberrant
subcutaneous
migration of parasite
Clonorchiasis – – – Abdominal pain,
diarrhoea
Fever, right upper
quadrant pain,
hepatomegaly,
cholangitis,
cholezystitis, chol-
angiocarcinoma
– Urticaria
Opisthorchiasis – – – Abdominal pain,
diarrhoea
Fever, right upper
quadrant pain,
hepatomegaly,
cholangitis /
cholezystitis, chol-
angiocarcinoma
– Urticaria
Fascioliasis – – Pulmonary
infiltrations, cough
Abdominal pain,
nausea, vomiting
Fever, right upper
quadrant pain,
hepatomegaly,
subcapsular hepatic
haemorrhage,
cholangitis /
cholezystitis, biliary
cirrhosis
Urticaria, aberrant
subcutaneous
migration of parasite
Intestinal fluke
infections
– – – Diarrhoea,
abdominal pain
– – –
ational sources (e.g., adventure travellers and water-based
sports activities) account for most leptospirosis cases and
outbreaks in industrialised countries, close contact with in-
fected animals and a contaminated environment remain the
major source of infection in most tropical countries, partic-
ularly in social-ecological contexts characterised by tradi-
tional agriculture and crowded urban settings, where inad-
equate sanitation and poverty prevail [96, 97].
Outbreaks accounting for thousands of deaths worldwide
underline the importance of leptospirosis as a re-emerging,
yet severely neglected infectious disease. It is widely
under-recognised due to difficult, poorly standardised dia-
gnosis and often mild and unspecific clinical presentations.
It is estimated that more than 500,000 severe cases occur
annually around the world [98] with a recent trend towards
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a higher proportion of infections with severe pulmonary
haemorrhages in endemic populations [99].
The typical combination of high fever, chills, calf myalgia,
headache and an abrupt onset of disease in the early stage
is seldom present, so that clinicians should include lepto-
spirosis in their differential diagnosis in any unexplained
febrile illness when risk factors for infection are present. In
a second disease stage, multiple organ failure may occur.
Hepatic dysfunction leading to jaundice and acute renal
failure are relatively frequent, but as a result of haemato-
genous spread, every organ including the central nervous
system (e.g., meningitis, meningoencephalitis) can be af-
fected. Laboratory confirmation of leptospirosis, e.g. by
microscopic agglutination test, is difficult and often time-
consuming, expensive, relatively insensitive and not avail-
able in many diagnostic centres, especially in the devel-
oping world [100]. Rapid serological testing, e.g. by an
ELISA detecting Leptospira-specific IgM antibodies, is
easy to perform and recommended by the WHO in
resource-constrained settings. The introduction of such as-
says represented a major step forward, as they are increas-
ingly becoming available throughout the tropics and allow
rapid confirmation of the diagnosis of suspected lepto-
spirosis cases. The diagnostic accuracy of the IgM assay,
however, has been reported to vary in different settings
[101, 102]. If severe leptospirosis is suspected, patients
should receive early antibiotic treatment with doxycycline,
penicillin G or ampicillin, even if recent meta-analyses
question the clinical benefit of such therapeutic regimens
[103]. Supportive treatment in the case of organ failure
(e.g., haemodialysis for acute renal failure) is essential,
while uncertainty remains regarding the use of immun-
osuppressive medication [96].
Treatment
Table 5 summarises the most widely used drugs and treat-
ment schemes for parasitic neglected tropical diseases. We
distinguish between large-scale community-based drug in-
terventions (an approach phrased “preventive chemother-
apy” [36]) that have become the key strategy in resource-
constrained settings of the developing world on one hand,
and individual patient management as applied in Switzer-
Figure 2
Life cycle of pathogenic Leptospira spp., the infectious agents of
leptospirosis.
land and other non-endemic settings on the other hand.
For example, while in Switzerland mebendazole is used as
100 mg two times daily for three days in the treatment of
common soil-transmitted helminthiases, a single dose of
500 mg is administered in preventive chemotherapy pro-
grammes in endemic settings. Given the ease of administra-
tion of the latter treatment scheme, as a result, non-medical
personnel (e.g., school teachers) can deliver these drugs to
large populations (e.g., all children in a school) as a public
health measure [36]. A disadvantage, however, is that the
efficacy of single doses is often lower than multiple dos-
ing. For example, while overall cure rates of 63–89% have
been reported for multiple doses of mebendazole against
T. trichiura infection, the cure rate of single-dose mebend-
azole is considerably lower (36%) [104]. Nevertheless, in
terms of parasite burden reduction (indirectly measured
by egg reduction rates), single dosing usually results in
high efficacy. Hence, preventive chemotherapy has been
endorsed by WHO as the key strategy for morbidity control
and tens of millions of people in developing countries are
treated every year [28, 36, 105–108].
It is interesting to note that the neglected tropical diseases
are often classified on the basis of available control tools,
hence separating between “tool-deficient” (costly and diffi-
cult to manage) and “tool-ready diseases” (safe and highly
efficacious drugs available for large-scale administration
by personnel outside the health sector) [36]. While the hel-
minth diseases summarised in tables 1 and 2 would fall into
the category of “tool-ready diseases”, for T. brucei rhodesi-
ense, currently available drugs cause serious adverse events
in a considerable proportion of all treated patients [58,
109].
Prevention and integrated control
While the unit of intervention to address the neglected trop-
ical diseases in the developing world is often at the pop-
ulation level (e.g., many of the helminth infections), some
diseases require enhanced patient management (e.g., Buruli
ulcer and human African trypanosomiasis). Clearly, the ad-
vent of safe, efficacious and cheap drugs that can be admin-
istered by non-health personnel spurred the way for pre-
ventive chemotherapy [36]. It should be noted, however,
that this strategy has several shortcomings. For example, it
is difficult to reach some of the most vulnerable popula-
tion groups. Moreover, compliance is an issue, particularly
when interventions must be repeated once or twice a year
for an unknown period of time. Indeed, a growing number
of people might feel healthy, and hence might not appreci-
ate the need for repeated treatment. Growing drug pressure
must be carefully monitored in terms of potential resistance
development. Importantly, rapid reinfection occurs, as pre-
ventive chemotherapy does not address the root behaviour-
al, ecological and socio-economic causes [18, 110]. These
issues call for preventive measures, such as improved ac-
cess to clean water, sanitation and hygiene have to been
emphasised [18, 111, 112]. Whenever resources allow, in-
tegrated control approaches should be pursued (i.e., imple-
mentation of a set of interventions that are readily tailored
to an endemic setting and adapted over time). This will re-
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Table 5: Recommended treatment for selected neglected tropical diseases, juxtaposing the situation in Switzerland (typical non-endemic setting) with large-scale control
emphasising preventive chemotherapy (in highly endemic settings).
Recommended treatment (individual patient
treatment in non-endemic setting, e.g.,
Switzerland)
Control (preventive chemotherapy in endemic setting)Disease
Drug / dosagea Drug / dosage
Hookworm infection Albendazole 400 mg OD x 3 d
Mebendazole 100 mg BID x 3 d
Ascariasis Albendazole 400 mg OD x 1 d
Mebendazole 100 mg BID x 3 d
Trichuriasis Albendazole 400 mg OD x 3 d
Mebendazole 100 mg BID x 3 d
Albendazole 400 mg OD x 1 d
Mebendazole 500 mg OD x 1 d
(Pyrantel pamoate) (10 mg/kg OD x 1 d)*
(Levamisole) (2.5 mg/kg OD x 1 d)*
Strongyloidiasis Ivermectin** 200 µg/kg OD x 2 d**
Albendazole 400 mg BID x 7 d
Ivermectin** 200 µg/kg OD x 2 d
Albendazole 400 mg OD x 1d or 400 mg BID x 3 d
Toxocariasis Albendazole 400 mg BID x 5-10 d
Mebendazole 100–200 mg BID x 5 d
Not available, however diethylcarbamazine (DEC) administered in the framework of the
global programme to eliminate lymphatic filariasis (GPELF) might have an impact on
toxocariasis
Trichinellosis Steroids (e.g., prednisone) 30–60 mg OD x
10-15 d tapering
plus albendazole 400 mg BID x 8-14 d
Schistosomiasis Praziquantel** 60 mg/kg OD on days 0 and
21–30 (S. haematobium, S. mansoni,
S. intercalatum)b;
25 mg/kg TID (S. mekongi, S. japonicum on
days 0 and 21–30)
Praziquantel 40 mg/kg single dose
Lymphatic filariasis Doxycycline 100 mg BID x 4 weeks +
ivermectin 200 µg/kg once ± albendazole 400
mg once
alternative: single dose diethylcarbamazine
(DEC) 6 mg/kg + albendazole 400 mg every
3–6 months
GPELF, launched by the Global Alliance to Eliminate Lymphatic Filariasis (GAELF;
http://www.filariasis.org). Ivermectin and albendazole are used in Africa and
diethylcarbamazine (DEC) and albendazole in areas outside Africa
Mansonellosis
- M. perstans
- M. ozzardi
- M. streptocerca
Albendazole 400 mg BID x 10 d
Mebendazole 100 mg BID x 30 d
Doxycyline 200 mg OD x 6 w
Ivermectin 200 μg/kg
Diethylcarbamazine (DEC) 6 mg/kg OD x 12
d
Ivermectin 200 μg/kg
Most individuals with Mansonella spp. infection are asymptomatic. Preventive
chemotherapy control programmes against lymphatic filariasis and soil-transmitted
helminthiasis are likely to have an impact on mansonellosis. Note that DEC should not
be administered in areas where onchocerciasis is endemic, due to the provocation of
serious adverse events, including exacerbation of ocular disease
Loiasis >100 MF/ml: albendazole 200 mg BID x 3
weeks (± plasmapheresis) + when <100 MF/
ml: diethylcarbamazine (DEC) x 3 weeks: day
1, 1 mg/kg; day 2, 3 mg/kg; day 3, 6 mg/kg;
days 4–21, each day 9 mg/kg
(MF = microfilaria)
Not available. Note that presence of loiasis interferes with mass drug treatment for
onchocerciasis as albendazole and ivermectin may cause serious adverse events in
loiasis patients
Onchocerciasis Doxycycline 100 mg BID x 4 weeks +
ivermectin* 200 µg/kg once + ivermectin* 200
µg/kg once after 4-6 months (*not in case of
Loa loa co-infection)
Africa: ivermectin every year for at least 15–17 years
South America: ivermectin twice every year until transmission has been interrupted
Leishmaniasis
Visceral cutaneous
Mucosal
Liposomal Amphotericin B 3 mg/kg i.v. days
1–5, 14 and 21
Various drugs and regimens and route of
application, according to species and clinical
manifestation [207].
Topical: 15% paromomycin / 12%
methylbenzethonium-chloride ointment, local
heat-/cryotherapy, pentavalent antimonials
intralesional
Systemic: pentavalent antimonials,
Miltefosine, liposomal Amphotericin B,
Ketoconazole
Active case detection, vector control and treatment are recommended in countries
suffering the greatest burden.
Human African
trypanosomiasis***
T. brucei gambiense
First (hemolymph.) stage
Second (meningoenceph.) stage
T. brucei rhodesiense
First (hemolymph.) stage
Second (meningoenceph.) stage
Pentamidine 4 mg/kg i.m. or i.v. (max. 200
mg/d) x 7 d
Nifurtimox-eflorninithine combination
treatment (NECT): nifurtimox (oral 15 mg/kg/
day (in 3 doses) x 10 d + eflornithine i.v. 400
mg/kg/day (in 2 doses) x 7 d
Suramin 20 mg/kg i.v. (max. 1 g/d) on days 1,
3, 7, 14 and 21
Melarsoprol 2.2 mg/kg i.v. x 10 d
National sleeping sickness control programmes including case detection and treatment
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Chagas disease Nifurtimox 8–10 mg/kg x 30-60-(90) d
or
Benznidazole 5–7.5 mg/kg x 30-60-(90) d
Surveillance and control programmes, with an emphasis on vector control ongoing
Paragonimiasis Praziquantel** 25 mg/kg TID x 3 d
Triclabendazole** 10 mg/kg OD x 1–2 d
Clonorchiasis Praziquantel** 25 mg/kg TID x 1 d
Opisthorchiasis Praziquantel** 25 mg/kg TID x 1 d
Fascioliasis Triclabendazole** 10 mg/kg OD (x 2 d)
Intestinal fluke infections Praziquantel** 25 mg/kg OD x 1 d
Preventive chemotherapy strategy currently under development
Dracunculiasis No drug available
Based on www.documed.ch: WHO report on neglected tropical diseases; WHO model formulary 2008; the Medical Letter Drugs for parasitic infections
a Dosages are oral if not specifically indicated.
b Recommended treatment regimen by the Swiss Tropical and Public Health Institute (Swiss TPH; Basel, Switzerland); others might still rely on a single 40 mg/kg oral
dose.
* Pyrantel pamoate and levamisole do not have a prominent role in preventive chemotherapy programmes since dosages are weight-based.
** Ivermectin, praziquantel and triclabendazole tablets are not available in Switzerland and are therefore often imported (e.g., from France). Eflornithine, suramin and
melarsoprol are not available in Switzerland; pentamidine is registered for Pneumocystis jiroveci pneumonia. Given the paucity of human African trypanosomiasis outside
Africa, treatment recommendations are based on studies conducted in endemic regions and the limited availability of the drugs outside endemic regions often determine
the choice of drug. Of note, drugs against human African trypanosomiasis can be obtained for free from WHO or from several medical centres in non-endemic countries
[206].
OD: once a day, BID: twice a day, TID: three times a day
quire a deep understanding of the demographic, health and
social-ecological systems contexts [18].
In Switzerland and other industrialised countries, the focus
is on the individual patient, in line with a growing emphasis
on personalised health care. However, preventive measures
(e.g., raising awareness among travellers about common
risk factors and mitigation strategies for neglected tropical
diseases in endemic countries) [113, 114] are as important
as adequate patient management of the returning traveller
and migrants.
Conclusions
Starting with an initial set of 13–15 diseases, there are
now over 40 helminth, protozoal, bacterial, viral, fungal
and ectoparasitic infections covered under the brand-name
of the neglected tropical diseases. Important gaps in our
understanding of the epidemiology and control of many
of the neglected tropical diseases remain, which calls for
additional funding, so that innovative research will even-
tually lead to new validated tools and strategies that can
be applied in the field. Although rarely seen in industrial-
ised countries, specific signs and symptoms should prompt
physicians to rule out neglected tropical diseases, particu-
larly among travellers, expatriates and migrants with a his-
tory of geographical and behavioural exposure to disease-
endemic areas. Importantly, many of those infections are
easily and effectively treated with short oral drug regimens
(e.g., soil-transmitted helminthiasis, including
strongyloidiasis). Other neglected tropical disease may
cause extensive and more costly investigations (e.g., leish-
maniasis, leprosy). In many cases, additional advice from,
or referral to specialists in tropical medicine is recommen-
ded for more detailed laboratory and clinical work up. Due
to the growing importance of neglected tropical diseases in
Switzerland and elsewhere in Europe, partially driven by
enhanced international travel, trade and migration, efforts
should be made by scientific societies and networks (e.g.,
Network for Education in International Health, tropEd in
short) to train and inform general practitioners on the pre-
vention, diagnosis, treatment and management of neglected
tropical diseases, including proper referral when need be.
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Figures (large format)
Figure 1
Life cycle of Strongyloides stercoralis. (Adapted from Olsen A, van Lieshout L, Marti H, Polderman T, Polman K, Steinmann P, et al.
Strongyloidiasis – the most neglected of the neglected tropical diseases? Trans R Soc Trop Med Hyg. 2009;103:967–72 [85]. © Elsevier, 2009.
Printed with permission).
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Figure 2
Life cycle of pathogenic Leptospira spp., the infectious agents of leptospirosis.
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